SynBalance focuses its activity to discover and unlock the health-enhancing potentialities of the biotics world. With a vision to a sustainable future for all human kind, driven by the Declaration of Intent – “Ode to the People” – SynBalance mission consists into deliver science-based probiotic solutions, taking care of people health through the modulation of the microbiota.
An example of people care is represented by FEMME, a patented probiotic ingredient composed by Lactiplantibacillus plantarumPBS067, Lacticaseibacillus rhamnosus LRH020 and Bifidobacterium animalis subsp. lactis BL050, a specific combination of proprietary strains designed to support women’s health across life stages. FEMME meets the need from younger to menopausal women, offering solutions against both yeast and bacterial infections, as well as for any kind of vaginal dysbiosis.
FEMME strains have been selected as the most performing in the prevention and support of women’s urogenital infections. A deep investigation of the mechanisms of action in several in-vitro models against a wide range of urogenital pathogens confirmed a strong antimicrobial spectrum, by inhibiting adhesion and growth of urogenital pathogens.
The antimicrobial and antiadhesive properties were evaluated on human vaginal epithelium infected with Candida glabrata, Neisseria gonorrheae, Trichomonas vaginalis, and human bladder epithelium infected by Escherichia coli.
The epithelial tissue permeability and integrity were assessed by transepithelial / transendothelial electrical resistance (TEER). Co-aggregation between probiotics and vaginal pathogens was also investigated. FEMME showed a full inhibition of T. vaginalis, and a reduction in C. glabrata and N. gonorrheae growth. A relevant antimicrobial activity was observed for each single strain against E. coli. TEER results demonstrated that none of the strains have negatively impaired the integrity of the 3D tissues while all the probiotics were able to form aggregates with the tested pathogens.
FEMME has been also clinically tested to evaluate the effectiveness in humans. The first clinical trial has explored the ability to colonize and persist in the vagina through oral intake. In a RDBPC trial 40 healthy women were enrolled and asked to take either FEMME, 3B CFU/day or placebo for 14 days. Results demonstrated that Femme strains can reach the vagina from the gastrointestinal tract, colonize and persist overtime (p<0,05).
FEMME has been further investigated to evaluate the reduction of relapses in women with Bacterial Vaginosis (BV): 75 women suffering from bacterial vaginosis were enrolled and treated with antibiotic for 5 days. Next 50 women continued with probiotic intake for 14 days after antibiotic treatment plus 7 days per month for the following 4 months, while the last 25 were monitored as control group without probiotic intake. Results demonstrated that the recurrence rate dropped at 16% in active group with respect to 40% of control group (p<0,01), in line with epidemiological data (40-60%). Last, another clinical trial recently concluded was performed on 50 post-menopausal women in order to evaluate FEMME efficacy on the restoration of vaginal microbiota, vaginal inflammatory status and well-being. Results demonstrated that in just 28 day women perceived a good replenishment of lactobacilli at vaginal level (+28%) as well as a strong reduction of pro-inflammatory cytokines IL-6, TNF-α and IL-1β (p<0.05). A significant improvement was achieved also for vaginal health through the Vaginal Health Index (p<0,001).
Currently in order to better complete the spectrum of positive clinical effect that FEMME has on women across life stages, another clinical trial on vulvovaginal candidiasis (VVC) is ongoing.
“The deep investigation on FEMME mechanism of action and its clinical efficacy on BV, VVC and menopause elevates it as a strong ally for women’s health. This also opens up to new areas of research where menopause, PMS or other chronic conditions are only the edge of the iceberg, paving the way to break the taboos surrounding women’s health.” underline Silvia Castegnaro, Product Manager.
Content sponsored by SynBalance
More information on: https://www.synbalance.care/probiotics/formulations/#filter=.urogenital